Asymchem Laboratories Injects RMB 1.05 Billion into Shanghai Subsidiary

Stock News07-30

Asymchem Laboratories (06821) announced on July 30, 2026, that it has entered into a capital increase agreement with its target company, Shanghai Asymchem Biotechnology Development Co., Ltd., along with Asymchem Biotechnology, Hillhouse Qirui, Zhuohai Daiheng, Dr. Hao Hong, Kailai Tongxin, and Haihe Kailai Fund. Under this agreement, the company and investors will collectively contribute RMB 1.2397 billion to the target company's share capital.

The company will contribute RMB 1.05 billion, Hillhouse Qirui will contribute RMB 177 million, and Dr. Hao Hong will contribute RMB 12.7 million. By signing this agreement, the target company will be able to introduce external investment through a capital increase and share expansion, aligning with the group's future development strategy.

This capital increase is designed to strengthen the target company's financial standing, meet its future capital expenditure and operational expense needs, and enhance its overall competitiveness. It will also support the development of the target company's CDMO business, which includes large molecule drugs, antibody-drug conjugates, mRNA drugs, and other advanced therapies.

As of the date of this announcement, the target company is a non-wholly owned subsidiary of the company, in which the company holds approximately 83.00% equity. The target company operates the group's CDMO business for large molecule drugs, antibody-drug conjugates, mRNA, and other advanced therapies. Upon completion of the capital increase, the target company will be held approximately 83.50% by the company and will remain a non-wholly owned subsidiary.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1120368588?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-30 21:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120368588","market":"nz","top_or_hot":-1,"title":"Asymchem Laboratories Injects RMB 1.05 Billion into Shanghai Subsidiary","media":"Stock News","content":"<p><b>Asymchem Laboratories (06821)</b> announced on July 30, 2026, that it has entered into a capital increase agreement with its target company, Shanghai Asymchem Biotechnology Development Co., Ltd., along with Asymchem Biotechnology, Hillhouse Qirui, Zhuohai Daiheng, Dr. Hao Hong, Kailai Tongxin, and Haihe Kailai Fund. Under this agreement, the company and investors will collectively contribute RMB 1.2397 billion to the target company's share capital.<br><br>The company will contribute RMB 1.05 billion, Hillhouse Qirui will contribute RMB 177 million, and Dr. Hao Hong will contribute RMB 12.7 million. By signing this agreement, the target company will be able to introduce external investment through a capital increase and share expansion, aligning with the group's future development strategy.<br><br>This capital increase is designed to strengthen the target company's financial standing, meet its future capital expenditure and operational expense needs, and enhance its overall competitiveness. It will also support the development of the target company's CDMO business, which includes large molecule drugs, antibody-drug conjugates, mRNA drugs, and other advanced therapies.<br><br>As of the date of this announcement, the target company is a non-wholly owned subsidiary of the company, in which the company holds approximately 83.00% equity. The target company operates the group's CDMO business for large molecule drugs, antibody-drug conjugates, mRNA, and other advanced therapies. Upon completion of the capital increase, the target company will be held approximately 83.50% by the company and will remain a non-wholly owned subsidiary.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Asymchem Laboratories Injects RMB 1.05 Billion into Shanghai Subsidiary</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAsymchem Laboratories Injects RMB 1.05 Billion into Shanghai Subsidiary\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-30 21:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Asymchem Laboratories (06821)</b> announced on July 30, 2026, that it has entered into a capital increase agreement with its target company, Shanghai Asymchem Biotechnology Development Co., Ltd., along with Asymchem Biotechnology, Hillhouse Qirui, Zhuohai Daiheng, Dr. Hao Hong, Kailai Tongxin, and Haihe Kailai Fund. Under this agreement, the company and investors will collectively contribute RMB 1.2397 billion to the target company's share capital.<br><br>The company will contribute RMB 1.05 billion, Hillhouse Qirui will contribute RMB 177 million, and Dr. Hao Hong will contribute RMB 12.7 million. By signing this agreement, the target company will be able to introduce external investment through a capital increase and share expansion, aligning with the group's future development strategy.<br><br>This capital increase is designed to strengthen the target company's financial standing, meet its future capital expenditure and operational expense needs, and enhance its overall competitiveness. It will also support the development of the target company's CDMO business, which includes large molecule drugs, antibody-drug conjugates, mRNA drugs, and other advanced therapies.<br><br>As of the date of this announcement, the target company is a non-wholly owned subsidiary of the company, in which the company holds approximately 83.00% equity. The target company operates the group's CDMO business for large molecule drugs, antibody-drug conjugates, mRNA, and other advanced therapies. Upon completion of the capital increase, the target company will be held approximately 83.50% by the company and will remain a non-wholly owned subsidiary.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"002821","symbol_name":"凯莱英","start_time":0,"source_url":"","article_id":"1120368588","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120368588","pubTimestamp":1785419776,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Asymchem Laboratories (06821) announced on July 30, 2026, that it has entered into a capital increase agreement with its target company, Shanghai Asymchem Biotechnology Development Co., Ltd., along...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"002821":"凯莱英","HELX":"Franklin Genomic Advancements ETF","BK0239":"医药制造","BK0132":"高送转概念","BK1191":"制药","06821":"凯莱英","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","WDNA":"WisdomTree BioRevolution Fund"},"translate_title":"凯莱英制药向上海子公司注资10.5亿元人民币","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WDNA":1,"HELX":1,"06821":1,"002821":1},"content_text":"Asymchem Laboratories (06821) announced on July 30, 2026, that it has entered into a capital increase agreement with its target company, Shanghai Asymchem Biotechnology Development Co., Ltd., along with Asymchem Biotechnology, Hillhouse Qirui, Zhuohai Daiheng, Dr. Hao Hong, Kailai Tongxin, and Haihe Kailai Fund. Under this agreement, the company and investors will collectively contribute RMB 1.2397 billion to the target company's share capital.The company will contribute RMB 1.05 billion, Hillhouse Qirui will contribute RMB 177 million, and Dr. Hao Hong will contribute RMB 12.7 million. By signing this agreement, the target company will be able to introduce external investment through a capital increase and share expansion, aligning with the group's future development strategy.This capital increase is designed to strengthen the target company's financial standing, meet its future capital expenditure and operational expense needs, and enhance its overall competitiveness. It will also support the development of the target company's CDMO business, which includes large molecule drugs, antibody-drug conjugates, mRNA drugs, and other advanced therapies.As of the date of this announcement, the target company is a non-wholly owned subsidiary of the company, in which the company holds approximately 83.00% equity. The target company operates the group's CDMO business for large molecule drugs, antibody-drug conjugates, mRNA, and other advanced therapies. Upon completion of the capital increase, the target company will be held approximately 83.50% by the company and will remain a non-wholly owned subsidiary.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1120368588","isCrawlerRequest":true}